NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Cash & Equivalents data on file, last reported at $210.6 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $210.6 million, up 208.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $210.6 million (up 208.56% YoY), and the FY2025 annual result was $210.6 million, up 208.56% from the prior year.
• Cash & Equivalents retreated to $210.6 million in Q4 2025 per NBP's latest filing, from $228.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $672.5 million in Q2 2021 and troughed at $53.6 million in Q1 2025.
• A 5-year average of $323.1 million and a median of $310.7 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 77.05% in 2024, then surged 208.56% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $551.1 million in 2021, then declined by 18.0% to $451.9 million in 2022, then tumbled by 34.18% to $297.4 million in 2023, then sank by 77.05% to $68.3 million in 2024, then surged by 208.56% to $210.6 million in 2025.
• Business Quant data shows NBP's Cash & Equivalents at $210.6 million in Q4 2025, $228.1 million in Q3 2025, and $165.4 million in Q2 2025.